

beginning in the fall, 2009, with funding to commence in spring, 2010. Interested parties may sign up to receive updates about AHRQ's Effective Health Care Program at <http://effectivehealthcare.ahrq.gov/>.

ADDRESSES: The future CER solicitations will be published in the NIH Guide: <http://grants.nih.gov/grants/guide/index.html>.

FOR FURTHER INFORMATION CONTACT: Until the solicitations are published, AHRQ cannot provide information on their contents.

Direct any general comments regarding the Effective Health Care program to: Lia Hotchkiss, MPH, PMP, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, Telephone: 301-427-1502, E-mail address:

Effectivehealthcare@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION:

Background

The Agency for Healthcare Research and Quality (AHRQ) has been supporting comparative effectiveness research for many years and since 2005 through AHRQ's Effective Health Care Program, which was authorized under Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The Effective Health Care program provides systematic reviews and develops other translational information and tools designed to inform health care decision making. The Effective Health Care Program advances the methodology of comparative effectiveness research (CER) and provides training grants to enhance the pool of researchers who can perform CER.

Comparative Effectiveness Research Initiative Description

Funding Opportunity
Announcements soliciting research grant applications for CER will provide \$148 million for evidence generation. This includes \$100 million for the Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE), a new, coordinated, national effort to establish a series of prospective pragmatic clinical comparative effectiveness studies that measure the benefits treatments produce in routine clinical practice and will include novel study designs focusing on real-world and under-represented populations (children, elderly, racial and ethnic minorities, and other understudied populations), and \$48 million for the establishment or enhancement of national patient registries that can be

used for researching the longitudinal effects of different interventions and collecting data on under-represented populations. Additional grant funding is expected to include \$29.5 million to support innovative translation and dissemination grants related to CER, as well as \$20 million to support training and career development in CER.

Requests for Contracts for CER will provide \$9.5 million to establish an infrastructure to identify new and/or emerging issues for comparative effectiveness review investments. Also, \$10 million will establish a Citizen's Forum to formally engage all stakeholders, and to expand and standardize public involvement in the entire Effective Health Care enterprise.

Additionally, AHRQ anticipates supporting other grants (\$1 million) and enhancing existing contracts for evidence synthesis (\$50 million), evidence generation (\$24 million), translation and dissemination (\$5 million), and salary and benefits for ARRA-related full-time equivalent positions (\$3 million).

Dated: August 11, 2009.

Carolyn M. Clancy,

AHRQ, Director.

[FR Doc. E9-19758 Filed 8-18-09; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; P01 Application.

Date: October 28, 2009.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

Contact Person: D. G. Patel, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 756, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682, pateldg@nidddk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: August 11, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-19889 Filed 8-18-09; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: September 9-10, 2009.

Time: September 9, 2009, 1:15 p.m. to 5:45 p.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols as well as related data management activities. Please check the meeting agenda at <http://oba.od.nih.gov/rdna/rdna.html> for more information.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Time: September 10, 2009, 8:30 a.m. to 11 a.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols as well as related data management activities. Please check the meeting agenda at <http://oba.od.nih.gov/rdna/rdna.html> for more information.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Room 750,